Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BOLT CVE:CZX TSE:FCR TSE:TRL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$5.70-4.4%$6.24$5.20▼$15.60$10.94M0.8911,804 shs15,531 shsCZXCanada Zinc MetalsC$0.31+∞C$0.31C$0.22▼C$0.39C$51.69MN/A238,645 shs118,500 shsFCRFirst Capital RealtyC$0.00C$18.60▼C$22.79N/AN/A468,009 shs3.04 million shsTRLTrilogy International PartnersC$0.00C$0.12▼C$2.50C$21.27MN/A68,686 shs239,293 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics-3.72%+1.53%-2.30%-13.62%-60.23%CZXCanada Zinc Metals0.00%0.00%0.00%0.00%0.00%FCRFirst Capital Realty0.00%0.00%0.00%0.00%0.00%TRLTrilogy International Partners0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBOLTBolt Biotherapeutics3.0339 of 5 stars3.22.00.00.02.73.31.3CZXCanada Zinc MetalsN/AN/AN/AN/AN/AN/AN/AN/AFCRFirst Capital RealtyN/AN/AN/AN/AN/AN/AN/AN/ATRLTrilogy International PartnersN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBOLTBolt Biotherapeutics 2.33Hold$50.00777.19% UpsideCZXCanada Zinc Metals 0.00N/AN/AN/AFCRFirst Capital Realty 4.00Strong BuyN/AN/ATRLTrilogy International Partners 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TRL, BOLT, CZX, and FCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025BOLTBolt BiotherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.005/13/2025BOLTBolt BiotherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$25.00 ➝ $20.00(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBOLTBolt Biotherapeutics$7.69M1.42N/AN/A$29.89 per share0.19CZXCanada Zinc MetalsN/AN/AN/AN/AN/AN/AFCRFirst Capital RealtyN/AN/AN/AN/AN/AN/ATRLTrilogy International PartnersC$407.64M0.00N/A0.77C$0.38 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBOLTBolt Biotherapeutics-$63.12M-$33.40N/AN/AN/AN/A-94.51%-59.07%8/12/2025 (Estimated)CZXCanada Zinc MetalsN/AN/A0.00∞N/AN/AN/AN/AN/AFCRFirst Capital RealtyN/AN/A0.00N/AN/AN/AN/AN/AN/ATRLTrilogy International PartnersN/AC$6.340.04N/A0.86N/AN/AN/AN/ALatest TRL, BOLT, CZX, and FCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025BOLTBolt Biotherapeutics-$6.40N/AN/AN/A$0.82 millionN/A5/12/2025Q1 2025BOLTBolt Biotherapeutics-$6.80-$5.80+$1.00-$0.29$0.77 million$1.22 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBOLTBolt BiotherapeuticsN/AN/AN/AN/AN/ACZXCanada Zinc MetalsN/AN/AN/AN/AN/AFCRFirst Capital RealtyN/AN/AN/AN/AN/ATRLTrilogy International PartnersC$1.31704.17%N/A20.69%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBOLTBolt Biotherapeutics0.483.133.13CZXCanada Zinc MetalsN/AN/AN/AFCRFirst Capital RealtyN/AN/AN/ATRLTrilogy International PartnersN/A5.923.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBOLTBolt Biotherapeutics86.70%CZXCanada Zinc MetalsN/AFCRFirst Capital RealtyN/ATRLTrilogy International PartnersN/AInsider OwnershipCompanyInsider OwnershipBOLTBolt Biotherapeutics30.90%CZXCanada Zinc MetalsN/AFCRFirst Capital RealtyN/ATRLTrilogy International PartnersN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBOLTBolt Biotherapeutics901.92 million1.33 millionNot OptionableCZXCanada Zinc Metals147,000166.73 millionN/ANot OptionableFCRFirst Capital RealtyN/AN/AN/ANot OptionableTRLTrilogy International Partners70,00088.63 millionN/ANot OptionableTRL, BOLT, CZX, and FCR HeadlinesRecent News About These CompaniesGPS PEP Expands User Base in Deal With Investment Advisory TrilogySeptember 11, 2024 | planadviser.comPThe Lord of the Rings Trilogy Theatrical Rerelease Dates Set for 2024 ReturnApril 26, 2024 | yahoo.comPeloton Capital invests in financial planning and wealth advisor TrilogyMarch 12, 2024 | pehub.comSG Enterprises II submits non-binding offer to acquire Trilogy InternationalDecember 18, 2023 | msn.comSG Enterprises II, LLC Submits Non-Binding Offer To Acquire Trilogy International Partners Inc.December 18, 2023 | finance.yahoo.comTrilogy International Partners Inc TRL.HNovember 21, 2023 | morningstar.comMTrilogy International Partners Inc. Reports Third Quarter 2023 Results and Appoints DirectorNovember 13, 2023 | finance.yahoo.comTrilogy Intl Partners: Top 10 Undervalued Telecommunication Services Industry Stocks (TRL-H)September 15, 2023 | theglobeandmail.comTrilogy International Partners Inc. Announces Completion of Distribution to ShareholdersJuly 28, 2023 | finance.yahoo.comBatman Arkham Trilogy For Switch Only Includes One Title On The Game CartridgeJune 26, 2023 | nintendolife.comNCompanies with the highest dividend payout growth over the last 5 years.May 14, 2023 | msn.comTrilogy International Ltd (TIL)May 14, 2023 | investing.comTrilogy International Partners Inc. Reports First Quarter 2023 ResultsMay 11, 2023 | finance.yahoo.comTrilogy International Partners GAAP EPS of -$0.03April 1, 2023 | seekingalpha.comTrilogy International Partners Inc. Announces New Listing on the NEX Board of the TSX Venture Exchange and Concurrent Voluntary Delisting from the TSXDecember 9, 2022 | finance.yahoo.comRian Johnson Confirms What’s Holding Back His Star Wars TrilogyOctober 31, 2022 | denofgeek.comD‘Rings of Power’ Finale Reveals Biggest Nod Yet to ‘Lord of the Rings’ Film TrilogyOctober 16, 2022 | indiewire.comIHilary Mantel, Double Booker Prize Winner and Author of Wolf Hall Trilogy, Dies SuddenlyOctober 1, 2022 | thedailybeast.comTNew On Peacock In October 2022: Halloween Ends, Back To The Future Trilogy, And Galaxy QuestSeptember 28, 2022 | gamespot.comGStar Wars leak: Luke Skywalker 'to get new trilogy' set before Force AwakensSeptember 28, 2022 | express.co.ukNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTRL, BOLT, CZX, and FCR Company DescriptionsBolt Biotherapeutics NASDAQ:BOLT$5.70 -0.26 (-4.36%) Closing price 03:59 PM EasternExtended Trading$5.70 0.00 (0.00%) As of 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.Canada Zinc Metals CVE:CZXC$0.31 +0.31 (+∞) As of 05/4/2018Canada Zinc Metals Corp. explores for and evaluates mineral resource properties in Canada. The company primarily explores for zinc-lead-silver base metals deposits. Its flagship property is the Akie property that consists of 46 mineral claims, which cover approximately 116 square kilometers, located in the Paleozoic Selwyn Basin, British Columbia. The company was formerly known as Mantle Resources Inc. and changed its name to Canada Zinc Metals Corp. in September 2008. Canada Zinc Metals Corp. was incorporated in 1988 and is headquartered in Vancouver, Canada.First Capital Realty TSE:FCRTrilogy International Partners TSE:TRLTrilogy International Partners Inc., together with its subsidiaries, provides wireless voice and data communications services in New Zealand, Bolivia, and internationally. It offers prepaid and postpaid payment plans, including local, international long distance, and roaming services to customers and international visitors roaming on its networks. The company also provides fixed broadband communications to residential and enterprise customers, as well as a range of mobile and fixed line services in New Zealand and Australia; and fixed public telephony and wireless broadband services in Bolivia. As of December 31, 2021, it had a distribution network of approximately 13 company owned stores, 170 dealers, and 8,300 other dealer points of presence in Bolivia; and a distribution network of approximately 20 company owned retail stores, 40 independent dealers, and 2,500 points of sale through national retail chains and grocery stores in New Zealand. The company's services cover an aggregate population of 16.8 million users. It also provides services through its online self-service store in New Zealand; and operates under the Viva brand name in Bolivia. Trilogy International Partners Inc. was founded in 1982 and is headquartered in Bellevue, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Fastenal Surges After Earnings Beat, Tariff Risks Loom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.